Evidence map›Paper›PMID 41064097›Full record

ArticleFrontiers in oncology2025

Clinical characteristics and prognosis of breast cancer patients with ovarian metastases.

Chunyan Gao, Yan Li, Xiaoping Ma, Zhenhui Zhao, Li Li, Dan Liu, Bingyu Li, Bing Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunyan GaoDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Yan LiDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Xiaoping MaDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Zhenhui ZhaoDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Li LiDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Dan LiuDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Bingyu LiDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Bing ZhaoDepartment of Breast Cancer, Affiliated Tumor Hospital of Xinjiang Medical University, The Clinical Research Center of Breast Tumor and Thyroid Tumor in Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to investigate the clinical characteristics, overall survival (OS), and prognostic factors associated with breast cancer patients who have ovarian metastasis (OM). Materials & methods: This retrospective single-center study analyzed 41 breast cancer patients with pathologically confirmed OM who underwent bilateral oophorectomy between 2011 and 2022. Data on clinical-pathological characteristics, molecular subtypes, detection methods, and survival were collected. The survival times were analyzed using Kaplan-Meier survival analysis. Prognostic factors were assessed through Cox regression models. Results: The cohort consisted of 33 (80.5%) invasive ductal carcinoma (IDC) and 8 (19.5%) invasive lobular carcinoma (ILC) cases. Most patients (87.8%) were hormone receptor-positive. Patients with ILC were significantly older at initial diagnosis than IDC patients (median 45 Conclusions: OM, which may not exhibit overt clinical manifestations in the early stage, significantly affects the survival of BC patients. The ILC histological type is associated with a particularly unfavorable post-OM prognosis, and the interval from initial diagnosis to OM is a key prognostic indicator. These findings may guide clinical management in these patients.

Indexed as

breast cancerinvasive ductal carcinomainvasive lobular carcinomaOS after OMovarian metastasis

Identifiers

PMID41064097
PMCPMC12500702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.